Rheumatology Indication Looks Promising for Efgartigimod

(MedPage Today) -- BARCELONA -- A drug targeting immunoglobulin G (IgG) currently approved for myasthenia gravis and chronic inflammatory demyelinating polyneuropathy (CIDP) now looks like it could take the rheumatology field by storm, if phase...